BR112014005518A2 - 2-(cromano-6-ilóxi)-tiazóis substituídos e a utilização dos mesmos como produtos farmacêuticos - Google Patents
2-(cromano-6-ilóxi)-tiazóis substituídos e a utilização dos mesmos como produtos farmacêuticosInfo
- Publication number
- BR112014005518A2 BR112014005518A2 BR112014005518A BR112014005518A BR112014005518A2 BR 112014005518 A2 BR112014005518 A2 BR 112014005518A2 BR 112014005518 A BR112014005518 A BR 112014005518A BR 112014005518 A BR112014005518 A BR 112014005518A BR 112014005518 A2 BR112014005518 A2 BR 112014005518A2
- Authority
- BR
- Brazil
- Prior art keywords
- chroman
- thiazoles
- yloxy
- pharmaceuticals
- substituted
- Prior art date
Links
- XFZODDHRWKDGLV-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-6-yloxy)-1,3-thiazole Chemical class C1=C2CCCOC2=CC=C1OC1=NC=CS1 XFZODDHRWKDGLV-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 102000001794 Sodium-Calcium Exchanger Human genes 0.000 abstract 1
- 108010040240 Sodium-Calcium Exchanger Proteins 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 230000004094 calcium homeostasis Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
resumo patente de invenção: "2-(cromano-6-ilóxi)-tiazóis substituídos e a utilização dos mesmos como produtos farmacêuticos". a presente invenção refere-se a 2-(cromano-6-ilóxi)-tiazóis substituídos da fórmula i, em que ar, r2, r3 e r4 são como definidos nas reivindicações. os compostos da fórmula i são inibidores do permutador de sódio-cálcio (ncx), especialmente do permutador de sódio-cálcio de subtipo 1 (ncx1), e são adequados para o tratamento de diversos distúrbios em que a homeostasia de cálcio intracelular é perturbada, tal como arritmias, insuficiência cardíaca e acidente vascular cerebral. a invenção, além disso, refere-se a processos para a preparação dos compostos da fórmula i, sua utilização como produtos farmacêuticos, e composições farmacêuticas compreendendo-os. 20694756v1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306128.7A EP2567958B1 (en) | 2011-09-12 | 2011-09-12 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
PCT/EP2012/067622 WO2013037724A1 (en) | 2011-09-12 | 2012-09-10 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014005518A2 true BR112014005518A2 (pt) | 2017-03-21 |
Family
ID=46801528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014005518A BR112014005518A2 (pt) | 2011-09-12 | 2012-09-10 | 2-(cromano-6-ilóxi)-tiazóis substituídos e a utilização dos mesmos como produtos farmacêuticos |
Country Status (28)
Country | Link |
---|---|
US (1) | US20140243292A1 (pt) |
EP (2) | EP2567958B1 (pt) |
JP (1) | JP5941986B2 (pt) |
AR (1) | AR087822A1 (pt) |
BR (1) | BR112014005518A2 (pt) |
CO (1) | CO6930365A2 (pt) |
CR (1) | CR20140130A (pt) |
CY (2) | CY1115953T1 (pt) |
DK (2) | DK2567958T3 (pt) |
EA (1) | EA027998B1 (pt) |
EC (1) | ECSP14013309A (pt) |
ES (2) | ES2528143T3 (pt) |
GT (1) | GT201400044A (pt) |
HK (1) | HK1182107A1 (pt) |
HR (2) | HRP20150025T1 (pt) |
HU (1) | HUE029233T2 (pt) |
MX (1) | MX343176B (pt) |
NI (1) | NI201400017A (pt) |
PE (1) | PE20141121A1 (pt) |
PL (2) | PL2567958T3 (pt) |
PT (2) | PT2567958E (pt) |
RS (2) | RS53748B1 (pt) |
SI (2) | SI2567958T1 (pt) |
TN (1) | TN2014000106A1 (pt) |
TW (1) | TWI549952B (pt) |
UA (1) | UA114407C2 (pt) |
UY (1) | UY34320A (pt) |
WO (1) | WO2013037724A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5941637B2 (ja) * | 2011-09-12 | 2016-06-29 | サノフイ | 置換2−(クロマン−6−イルオキシ)−チアゾール及び医薬としてのその使用 |
TWI633095B (zh) | 2013-03-08 | 2018-08-21 | 賽諾菲公司 | 經取代-6-基氧基-環烷類及其作為醫藥品之用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4168380A (en) | 1978-04-21 | 1979-09-18 | Hoffmann-La Roche Inc. | 7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid |
JPH0967336A (ja) | 1995-09-04 | 1997-03-11 | Kanebo Ltd | 新規なイソチオウレア誘導体 |
CN1166623C (zh) | 1997-03-27 | 2004-09-15 | 大正制药株式会社 | 2-苯氧基苯胺类衍生物 |
EE200200123A (et) | 1999-09-10 | 2003-08-15 | Merck & Co., Inc. | Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine |
AU2001295951A1 (en) | 2000-10-18 | 2002-04-29 | Senju Pharmaceutical Co. Ltd. | Novel 4-benzyloxyphenyl derivative and use thereof |
FI20011507A0 (fi) | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
JPWO2004000813A1 (ja) | 2002-06-25 | 2005-10-20 | アステラス製薬株式会社 | フェノキシピリジン誘導体又はその塩 |
ATE510073T1 (de) * | 2002-12-13 | 2011-06-15 | Hansgrohe Ag | Brausehalter |
FI20030030A0 (fi) * | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
JP2006199941A (ja) * | 2004-12-20 | 2006-08-03 | Chisso Corp | クロマン環を有する化合物を含有する液晶組成物 |
WO2007073497A2 (en) * | 2005-12-22 | 2007-06-28 | Icagen, Inc. | Calcium channel antagonists |
JP5092111B2 (ja) | 2007-02-05 | 2012-12-05 | トーアエイヨー株式会社 | ブトキシアニリン誘導体 |
EP2103939A1 (en) | 2008-03-20 | 2009-09-23 | sanofi-aventis | Fluorescence based assay to detect sodium/calcium exchanger (NCX) "reverse mode" modulating compounds |
US8354454B2 (en) | 2008-10-01 | 2013-01-15 | Merck Sharp & Dohme Corp. | Prodrugs of oxazolidinone CETP inhibitors |
JP5941637B2 (ja) * | 2011-09-12 | 2016-06-29 | サノフイ | 置換2−(クロマン−6−イルオキシ)−チアゾール及び医薬としてのその使用 |
US8912224B2 (en) * | 2011-09-12 | 2014-12-16 | Sanofi | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
-
2011
- 2011-09-12 RS RS20150022A patent/RS53748B1/en unknown
- 2011-09-12 DK DK11306128.7T patent/DK2567958T3/en active
- 2011-09-12 PT PT113061287T patent/PT2567958E/pt unknown
- 2011-09-12 EP EP11306128.7A patent/EP2567958B1/en active Active
- 2011-09-12 SI SI201130350T patent/SI2567958T1/sl unknown
- 2011-09-12 ES ES11306128.7T patent/ES2528143T3/es active Active
- 2011-09-12 PL PL11306128T patent/PL2567958T3/pl unknown
-
2012
- 2012-09-10 WO PCT/EP2012/067622 patent/WO2013037724A1/en active Application Filing
- 2012-09-10 UA UAA201403780A patent/UA114407C2/uk unknown
- 2012-09-10 PE PE2014000332A patent/PE20141121A1/es active IP Right Grant
- 2012-09-10 PL PL12756214.8T patent/PL2755970T3/pl unknown
- 2012-09-10 DK DK12756214.8T patent/DK2755970T3/en active
- 2012-09-10 SI SI201230609A patent/SI2755970T1/sl unknown
- 2012-09-10 BR BR112014005518A patent/BR112014005518A2/pt not_active Application Discontinuation
- 2012-09-10 HU HUE12756214A patent/HUE029233T2/en unknown
- 2012-09-10 EP EP12756214.8A patent/EP2755970B1/en active Active
- 2012-09-10 ES ES12756214.8T patent/ES2578184T3/es active Active
- 2012-09-10 JP JP2014529013A patent/JP5941986B2/ja active Active
- 2012-09-10 MX MX2014002673A patent/MX343176B/es active IP Right Grant
- 2012-09-10 EA EA201490618A patent/EA027998B1/ru not_active IP Right Cessation
- 2012-09-10 RS RS20160442A patent/RS54851B1/sr unknown
- 2012-09-10 PT PT127562148T patent/PT2755970T/pt unknown
- 2012-09-10 AR ARP120103328A patent/AR087822A1/es unknown
- 2012-09-11 TW TW101133072A patent/TWI549952B/zh not_active IP Right Cessation
- 2012-09-12 UY UY0001034320A patent/UY34320A/es not_active Application Discontinuation
-
2013
- 2013-08-13 HK HK13109436.8A patent/HK1182107A1/xx not_active IP Right Cessation
-
2014
- 2014-03-03 NI NI201400017A patent/NI201400017A/es unknown
- 2014-03-07 GT GT201400044A patent/GT201400044A/es unknown
- 2014-03-11 US US14/204,220 patent/US20140243292A1/en not_active Abandoned
- 2014-03-11 TN TNP2014000106A patent/TN2014000106A1/en unknown
- 2014-03-18 CR CR20140130A patent/CR20140130A/es unknown
- 2014-04-08 CO CO14075065A patent/CO6930365A2/es unknown
- 2014-04-11 EC ECSP14013309 patent/ECSP14013309A/es unknown
-
2015
- 2015-01-09 HR HRP20150025AT patent/HRP20150025T1/hr unknown
- 2015-01-23 CY CY20151100076T patent/CY1115953T1/el unknown
-
2016
- 2016-06-16 HR HRP20160687TT patent/HRP20160687T1/hr unknown
- 2016-06-28 CY CY20161100582T patent/CY1118141T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20160327A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
BR112014013661A8 (pt) | derivados de nucleosídeos 2,4-difluoro-2-metil substituídos como inibidores de replicação de hcv-rna | |
BR112014015845A8 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
IL203448A (en) | History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them | |
BR112015010908A2 (pt) | derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo | |
BR112015020650A2 (pt) | inibidores de histona demetilases | |
MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
BR112014001801A2 (pt) | indazóis | |
BRPI0911243B8 (pt) | derivados de benzofurano, benzotiofeno, benzotiazol, e composição farmacêutica | |
BR112015002118A2 (pt) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
BR112014014452A2 (pt) | derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos | |
BR112014016648A8 (pt) | derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos | |
DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
BR112014001587A2 (pt) | derivados de ácido 3-(tiazol-4-carbonil)- ou 3-(tiazol-2-carbonil) amino-propiônico substituídos e seu uso como produtos farmacêuticos | |
BR112013030264A2 (pt) | ácidos acéticos de benzociclohepteno | |
BR112014001518A2 (pt) | derivados de ácido 3-heteroaroilamino-propiônico e seus usos como produtos farmacêuticos | |
BR112014014877A2 (pt) | derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos | |
BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
BR112015015250A2 (pt) | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos | |
BR112014005518A2 (pt) | 2-(cromano-6-ilóxi)-tiazóis substituídos e a utilização dos mesmos como produtos farmacêuticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |